Author | Franco M. Muggia, MD

Articles

Carboplatin/Paclitaxel Induction in Ovarian Cancer: The Finer Points

August 15, 2018

The regimen consisting of carboplatin and paclitaxel represents the backbone of ovarian cancer treatment. Here, we reflect on our experience administering the carboplatin/paclitaxel regimen to scores of ovarian cancer patients over the past decade and a half.

HE4: Another ‘Player’ in the Epithelial Tumor Marker Arena?

June 15, 2013

While a prominent role for HE4 in these areas remains to be determined, this thorough review of HE4 demonstrates that the biomarker is complementary to, and occasionally more useful than, the widely used CA 125 in the management of gynecologic malignancies.

Targeted Therapy: Its Status and Promise in Selected Solid Tumors Part I

October 23, 2012

We describe areas where major inroads were initially achieved by targeting angiogenesis and by unraveling pathways in the heterogeneous tumors of mesenchymal origin-spurred by the identification of c-Kit–activating mutations in GIST and the regressions that ensued when tumors harboring these mutations were exposed to the tyrosine kinase inhibitor imatinib (Gleevec).